Company intelligence / Profile preview

APRINOIA Therapeutics

Cambridge, Massachusetts, United Statesaprinoia.com ↗

Ownership: Private
Employees: ~72
Development stage: Phase 1

Overview

APRINOIA has received FDA "Study May Proceed" letter for Phase 3 study of APN-1607 (florzolotau) for PSP diagnosis in January 2024. In May 2024, the FDA granted Fast Track Designation for APN-1607. Their therapeutic antibody APNmAb005 received FDA clearance to begin Phase 1 trials in April 2022.

Therapeutic areas: Neurology
Modalities: PET imaging tracersmonoclonal antibodiessmall moleculesprotein degraders
Industry: Biotech

Drug pipeline

4 assets

florzolotau

3 more assets in the full pipeline.

Request access →

Partnerships

Michael J. Fox FoundationLundbeckAbbVieInsilico MedicineAlzheimer's Drug Discovery Foundation (ADDF)

Beyond the preview

Go deeper on APRINOIA Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APRINOIA Therapeutics.

Explore the full profile